Tumor cell ferroptosis in antitumor immunity and immunotherapy efficacy.
Tumor cell ferroptosis in antitumor immunity and immunotherapy efficacy. J Immunother Cancer. 2026 Jun 19; 14(6).
PMID: 42320985
Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets.
Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets. J Immunother Cancer. 2026 Apr 09; 14(4).
PMID: 41956544
Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance).
Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance). Cancer Immunol Res. 2026 Mar 04; 14(3):423-433.
PMID: 41505731
Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy.
Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy. Cancer Immunol Res. 2025 Aug 01; 13(8):1284-1302.
PMID: 40512146
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma. Nat Med. 2025 Jul; 31(7):2385-2396.
PMID: 40473950
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Adv. 2025 May 13; 9(9):2144-2152.
PMID: 39928953
PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells.
PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 04 02; 13(4):547-559.
PMID: 39808445
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Mar; 639(8054):E18.
PMID: 40000750
Targeting molecular pathways to control immune checkpoint inhibitor toxicities.
Targeting molecular pathways to control immune checkpoint inhibitor toxicities. Trends Immunol. 2025 01; 46(1):61-73.
PMID: 39732529
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 01; 637(8048):1218-1227.
PMID: 39663448